Related Experiment Video
Updated: Jul 3, 2026
07:36
Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
Published on: December 23, 2022
Curcumin analogues suppress cellular pro-inflammatory mediators and reduce edema
Kifayat Ullah1, Wenyun Zhu2, Syed Wadood Ali Shah3
1Department of Pharmacy, Shaheed Benazir Bhutto University Sheringal Dir (Upper), Dir, 18000, Pakistan.
Naunyn-Schmiedeberg'S Archives of Pharmacology
|July 1, 2026
Summary
Curcumin analogues K1 and K4 show significant anti-inflammatory effects by reducing swelling in mouse models. These compounds downregulate key inflammatory markers, demonstrating potential for treating acute inflammation.
Area of Science:
- Pharmacology
- Medicinal Chemistry
- Immunology
Background:
- Inflammation is a critical biological response involving cytokines and signaling pathways.
- Curcumin is known to modulate inflammatory pathways, but its analogues' roles require further investigation.
Purpose of the Study:
- To explore the in vitro and in vivo anti-inflammatory potential of synthesized curcumin analogues (K1-K4).
Main Methods:
- Synthesis of four curcumin analogues (K1-K4).
- Assessment of anti-inflammatory efficacy in carrageenan- and histamine-induced edema models in mice.
- In vitro analysis of protein and mRNA expression of inflammatory mediators in RAW264.7 cells.
Main Results:
- Curcumin analogues K1 and K4 significantly reduced carrageenan-induced paw edema and histamine-mediated ear and paw edema in mice.
- K1 and K4 demonstrated maximum inhibition of paw edema (over 62%) at 20 mg/kg.
- Analogues (except K2) downregulated iNOS, COX2, and p-p65 protein levels and inflammatory cytokine mRNA expression in RAW264.7 cells.
Conclusions:
- Curcumin analogues K1 and K4 exhibit significant anti-inflammatory activity in acute inflammation models.
- These analogues suppress key pro-inflammatory mediators, indicating therapeutic potential.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:28Inflammatory Response
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.